高度侵袭性TP53/MDM2突变上尿路上皮癌一线免疫化疗持续完全缓解病例报告数据表

数据集获取（Figshare）

• 源站标题：DataSheet_1_Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review.pdf
• DOI：10.3389/fonc.2023.1119343.s001
• 发布日期：2023-06-23
• 文件数：1 个
• 文件总体积：2.10 MB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Sustained_complete_response_to_first-line_immunochemotherapy_for_highly_aggressive_TP53_MDM2-mutated_upper_tract_urothelial_carcinoma_with_ERBB2_mutations_luminal_immune-infiltrated_contexture_and_non-mesenchymal_state_a_case_re/23567025

命令行下载

curl -L -o "DataSheet_1_Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with.pdf" "https://ndownloader.figshare.com/files/41345868"

文件清单

• DataSheet_1_Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with.pdf（2.10 MB）

文件总体积 2.10 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

BackgroundUpper tract urothelial carcinoma (UTUC) is a rare malignancy. The management of metastatic or unresectable UTUC is mainly based on evidence extrapolated from histologically homologous bladder cancer, including platinum-based chemotherapy and immune checkpoint inhibitor alone, whereas UTUC exhibits more invasiveness, worse prognosis, and comparatively inferior response to treatments. First-line immunochemotherapy regimens have been attempted in clinical trials for unselected naïve-treated cases, but their efficacies relative to standard chemo- or immuno-monotherapy still remain controversial. Here, we present a case of highly aggressive UTUC for whom comprehensive genetic and phenotypic signatures predicted sustained complete response to first-line immunochemotherapy.
Case presentationA 50-year-old man received retroperitoneoscopic nephroureterectomy and regional lymphadenectomy for high-risk locally advanced UTUC. Postoperatively, he developed rapid progression of residual unresectable metastatic lymph nodes. Pathologic analysis and next-generation sequencing classified the tumor as highly aggressive TP53/MDM2-mutated subtype with features more than expression of programmed death ligand-1, including ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state. Immunochemotherapy combining gemcitabine, carboplatin, and off-label programmed death-1 inhibitor sintilimab was initiated, and sintilimab monotherapy was maintained up to 1 year. Retroperitoneal lymphatic metastases gradually regressed to complete response. Blood-based analyses were performed longitudinally for serum tumor markers, inflammatory parameters, peripheral immune cells, and circulating tumor DNA (ctDNA) profiling. The ctDNA kinetics of tumor mutation burden and mean variant allele frequency accurately predicted postoperative progression and sustained response to the following immunochemotherapy, which were mirrored by dynamic changes in abundances of ctDNA mutations from UTUC-typical variant genes. The patient remained free of recurrence or metastasis as of this publishing, over 2 years after the initial surgical treatment.
ConclusionImmunochemotherapy may be a pr

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fonc.2023.1119343.s001（source: https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Sustained_complete_response_to_first-line_immunochemotherapy_for_highly_aggressive_TP53_MDM2-mutated_upper_tract_urothelial_carcinoma_with_ERBB2_mutations_luminal_immune-infiltrated_contexture_and_non-mesenchymal_state_a_case_re/23567025）。